GlassScriptPhysician profile
Paul Snyder
NPI 1477551398
$4,901.24
in general payments reported to CMS, 2019-2025
22 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2021: $334 · 2022: $529 · 2023: $672 · 2024: $1,087 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,238 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,238.45 |
| Education | $279.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.26 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $829.58 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Janssen Biotech, INC. | $759.64 | 2019-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $416.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $383.48 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $230.98 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $219.70 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $179.18 | 2019-2025 | Bimzelx |
| Amgen INC. | $146.93 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $146.28 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $122.39 | 2021-2025 | Nemluvio, Dysport |
| Pfizer INC. | $106.83 | 2019-2025 | |
| Genzyme Corporation | $93.63 | 2022-2025 | |
| Revance Therapeutics, INC. | $63.66 | 2024 | Daxxify |
| Fresenius Kabi USA, LLC | $48.10 | 2024-2025 | Idacio, Adalimumab-Aacf |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.98 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.44 | 2024-2025 | Jublia, Cabtreo, Siliq |
| Sun Pharmaceutical Industries INC. | $33.86 | 2023 | Ilumya, Absorica Ld, Winlevi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2024 | Spevigo |
| Merck Sharp & Dohme LLC | $19.54 | 2024 | Keytruda |
| Botanix Sb INC | $17.70 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $16.48 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.